PMID- 35987483
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221207
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 184
DP  - 2022 Oct
TI  - Probiotics and synbiotics supplementation improve glycemic control parameters in 
      subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed 
      systematic review, meta-analysis, and meta-regression of randomized clinical 
      trials.
PG  - 106399
LID - S1043-6618(22)00344-9 [pii]
LID - 10.1016/j.phrs.2022.106399 [doi]
AB  - Probiotics and synbiotics have been proposed to exhibit an important role in 
      glucose homeostasis and maintain the balance of the gut microbiota. However, 
      clinical trials have shown mixed findings. Therefore, we conducted a systematic 
      review and meta-analysis of all eligible randomized controlled trials (RCTs) 
      examining the effects of probiotics and synbiotics intake on glycemic outcomes 
      among individuals with prediabetes and type 2 diabetes mellitus (T2DM). The 
      PubMed/Medline, Scopus, ISI Web of Science, and Cochrane library were searched up 
      to March 2022 for published RCTs exploring the effectiveness of probiotics and 
      synbiotics compared to control on glycemic outcomes. The random-effects model was 
      applied in order to the estimation of 95 % confidence interval (CI) and the 
      weighted mean difference (WMD) for each endpoint. Meta-analysis of forty-six RCTs 
      (3067 participants) showed that probiotics and synbiotics supplementation 
      significantly reduced fasting plasma glucose (FPG) (weighted mean difference 
      (WMD): - 11.18 mg/dl, 95 % CI: - 13.60, - 8.75, p <0.001), fasting insulin serum 
      level (WMD: -1.23 microIU/ml, 95 % CI: -1.76, -0.71, p <0.001), hemoglobin A1c 
      (HbA1c) (WMD: -0.35 %, 95 % CI: -0.44, -0.26, p<0.001), and homeostatic model 
      assessment of insulin resistance (HOMA-IR) (WMD: -0.87, 95 % CI: -1.09, -0.65, 
      p<0.001). Additionally, probiotics and synbiotics intake resulted in an increase 
      in values of quantitative insulin-sensitivity check index (QUICKI) (WMD: 0.01, 
      95 % CI: 0.00, 0.01, p<0.001). However, probiotics and synbiotics consumption did 
      not change glucose values following oral glucose tolerance test (OGTT). Our 
      findings suggest that probiotic and synbiotic intake has favorable effects on 
      glycemic profile in patients with prediabetes and T2DM.
CI  - Copyright (c) 2022 Elsevier Ltd. All rights reserved.
FAU - Naseri, Kaveh
AU  - Naseri K
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Saadati, Saeede
AU  - Saadati S
AD  - Department of Medicine, School of Clinical Sciences, Monash University, 
      Melbourne, Australia.
FAU - Ashtary-Larky, Damoon
AU  - Ashtary-Larky D
AD  - Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of 
      Medical Sciences, Ahvaz, Iran.
FAU - Asbaghi, Omid
AU  - Asbaghi O
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Ghaemi, Farahnaz
AU  - Ghaemi F
AD  - Department of Microbiology, Kerman Branch, Islamic Azad University, Kerman, Iran.
FAU - Pashayee-Khamene, Fereshteh
AU  - Pashayee-Khamene F
AD  - Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, 
      Ahvaz, Iran.
FAU - Yari, Zahra
AU  - Yari Z
AD  - Department of Nutrition Research, National Nutrition and Food Technology Research 
      Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - de Courten, Barbora
AU  - de Courten B
AD  - Department of Medicine, School of Clinical Sciences, Monash University, 
      Melbourne, Australia; School of Health and Biomedical Sciences, RMIT University, 
      Bundoora, Australia. Electronic address: barbora.decourten@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220818
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulins)
SB  - IM
MH  - Blood Glucose/analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dietary Supplements
MH  - Glycated Hemoglobin/analysis
MH  - Glycemic Control
MH  - Humans
MH  - *Insulin Resistance
MH  - *Insulins/therapeutic use
MH  - *Prediabetic State/drug therapy
MH  - *Probiotics/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - *Synbiotics
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Glycemic profile
OT  - Meta-analysis
OT  - Prediabetes
OT  - Probiotic
OT  - Synbiotic
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/21 06:00
MHDA- 2022/10/18 06:00
CRDT- 2022/08/20 19:35
PHST- 2022/06/19 00:00 [received]
PHST- 2022/08/14 00:00 [revised]
PHST- 2022/08/14 00:00 [accepted]
PHST- 2022/08/21 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/08/20 19:35 [entrez]
AID - S1043-6618(22)00344-9 [pii]
AID - 10.1016/j.phrs.2022.106399 [doi]
PST - ppublish
SO  - Pharmacol Res. 2022 Oct;184:106399. doi: 10.1016/j.phrs.2022.106399. Epub 2022 
      Aug 18.